Skip to main content
. 2018 Dec 18;19(12):4105. doi: 10.3390/ijms19124105

Figure 4.

Figure 4

Chronic treatment with ISO-1 and compound 31 prevents the development of pulmonary hypertension in bleomycin (BLM)-injected mice. (A) Right ventricular systolic pressure (RVSP) in control or BLM-injected mice treated, or not, with ISO-1 or compound 31. (B) Representative images of α-smooth muscle actin (α-SMA) staining and quantification of the percentage of muscularized pulmonary arteries in control or BLM-injected mice treated, or not, with ISO-1 or compound 31. (C) Assessment of RV hypertrophy using the Fulton index (RV/(LV + S)) in control or BLM-injected mice treated, or not, with ISO-1 or compound 31. Values are means ± SEM (n = 4–8), where n represents the number of mice. * p < 0.05; *** p < 0.001; **** p < 0.0001 compared to control mice. # p = 0.05; ## p < 0.01 compared to BLM-injected mice. Scale bar = 50 μm in all sections. α-SMA = α-smooth muscle actin; AU = arbitrary unit; LV = left ventricle; RV = right ventricle; S = septum.